Clinical Trial Update: Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating dabrafenib plus trametinib for BRAF V600 mutation-positive melanoma has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Dabrafenib (Dabrafenib)
• Trametinib (trametinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Cancer, Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2021-03-17